{"id":"W4410958737","doi":"10.1016/j.annonc.2025.05.009","title":"Dostarlimab and niraparib in primary advanced ovarian cancer","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":false,"ca_institutions":"McGill University Health Centre","funders":"PharmaMar; Genesis Pharma; Astellas Pharma; Eisai; Seagen; Verastem Oncology; Pfizer; Incyte; Ipsen; Clovis Oncology; AstraZeneca; Novocure; Daiichi Sankyo Europe; Gilead Sciences; Intuitive Surgical; Regeneron Pharmaceuticals; EMD Serono; Mersana Therapeutics; Karyopharm Therapeutics; Bristol-Myers Squibb; Eli Lilly and Company; American Society of Clinical Oncology; GlaxoSmithKline; Amgen","keywords":"Medicine; Ovarian cancer; Oncology; Primary (astronomy); Gynecology; Internal medicine; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006981751,0.0002034747,0.0009120748,0.0002889809,0.0001969013,0.0004691272,0.0002436534,0.0003155945,0.003490337],"category_scores_gemma":[0.001249467,0.0001130613,0.0007202705,0.0003833769,0.0002264178,0.0004841164,0.0003740526,0.001270854,0.0003477752],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008321179,"about_ca_system_score_gemma":0.0008738801,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006280162,"about_ca_topic_score_gemma":0.002964017,"domain_scores_codex":[0.9996914,0.0001343985,0.00003660819,0.00003204619,0.00004424441,0.00006141276],"domain_scores_gemma":[0.9996878,0.000112569,0.00004608175,0.00002634593,0.00003049099,0.00009668186],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.06434257,0.001976604,0.02204303,0.002465451,0.001046366,0.0009067209,0.0002211042,0.00514558,0.01130898,0.001455609,0.01632718,0.8727608],"study_design_scores_gemma":[0.07435717,0.1526534,0.3336843,0.001488358,0.003784759,0.01571492,0.001183019,0.01398707,0.02914075,0.0106091,0.363226,0.0001711255],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.8251473,0.1365778,0.0007435317,0.007962624,0.001407325,0.0004663229,0.00141559,0.0001555933,0.02612382],"genre_scores_gemma":[0.9664714,0.02521776,0.0009219824,0.001466535,0.0003752286,0.0001790916,0.001290043,0.00002018863,0.004057826],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003490337,"threshold_uncertainty_score":0.01167631,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05532924224225995,"score_gpt":0.4313976606856236,"score_spread":0.3760684184433636,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}